


**AMENDMENTS TO THE CLAIMS**

This listing of claims replaces all prior listing of claims in the application.

1. (Currently amended) A compound of structural formula I:



a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

n is 0, 1, or 2;

a and b are each independently chosen from a double bond and a single bond;

X and Y are each independently chosen from hydrogen, halogen, hydroxy, C<sub>1-4</sub> alkoxy,

hydroxymethyl, and C<sub>1-3</sub> alkyl, wherein said alkoxy and alkyl are each optionally substituted with one to seven fluorine atoms; or

X and Y, together with the carbon atom to which they are attached, can optionally form a C<sub>3-6</sub> cycloalkyl group;

R<sup>1</sup> is chosen from hydrogen, carbonyl(C<sub>1-3</sub> alkyl), hydroxy, C<sub>1-4</sub> alkoxy, halogen, hydroxymethyl, (C<sub>0-6</sub> alkyl)<sub>2</sub>amino, and C<sub>1-3</sub> alkyl, wherein said alkoxy and alkyl are each optionally substituted with one to seven fluorine atoms;

R<sup>4</sup> is chosen from halogen, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, (CH<sub>2</sub>)<sub>n</sub>-phenyl, and (CH<sub>2</sub>)<sub>n</sub>-naphthyl; and

wherein R<sup>4</sup> is optionally substituted with one or more substituents each independently chosen from cyano, carboxy, halogen, hydroxy, oxo, C<sub>1-4</sub> alkoxy, and C<sub>1-4</sub> alkylthio; or

~~R<sup>4</sup>, together with the carbon atom to which it is attached, form a carbonyl or a cyclopropyl group and provided that a represents a single bond; or~~

~~R<sup>1</sup> and R<sup>4</sup>, together with the atoms to which they are attached, form a 5- or 6-membered ring system optionally containing an additional heteroatom chosen from O, S, and NC<sub>1-4</sub> alkyl;~~

R<sup>2</sup> is hydrogen or C<sub>1-4</sub> alkyl, wherein said C<sub>1-4</sub> alkyl is optionally substituted with one or more substituents independently selected from halogen, hydroxy, C<sub>1-4</sub> alkoxy, and C<sub>1-4</sub> alkylamino;

R<sup>3</sup> is selected from

~~(CH<sub>2</sub>)<sub>n</sub>-aryl, wherein said aryl is optionally substituted with one or more substituents independently chosen from R<sup>5</sup>; and~~

~~(CH<sub>2</sub>)<sub>n</sub>-heteroaryl, wherein said heteroaryl is optionally substituted with one or more substituents independently chosen from R<sup>5</sup>;~~

~~C<sub>1-10</sub> alkyl, wherein said C<sub>1-10</sub> alkyl is optionally substituted with one or more substituents independently chosen from R<sup>6</sup>; or~~

~~R<sup>2</sup> and R<sup>3</sup>, together with the nitrogen atom to which they are attached, form a 5- or 6-membered saturated ring fused with a 5- or 6-membered aromatic ring system having 0, 1, or 2 heteroatoms selected from N, O, and S; and~~

wherein any methylene (CH<sub>2</sub>) carbon atom in (CH<sub>2</sub>)<sub>n</sub> is optionally substituted with one or more groups independently selected from halogen, hydroxy, and C<sub>1-4</sub> alkyl optionally substituted with one or more halogen moieties; or two substituents when on the same methylene (CH<sub>2</sub>) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group;

R<sup>5</sup> is chosen from: hydrogen, halogen, (carbonyl)<sub>0-1</sub>C<sub>1-10</sub> alkyl, (carbonyl)<sub>0-1</sub>C<sub>2-10</sub> alkenyl, (carbonyl)<sub>0-1</sub>C<sub>2-10</sub> alkynyl, C<sub>3-8</sub> cycloalkyl C<sub>0-10</sub> alkyl(carbonyl)<sub>0-1</sub>, C<sub>3-8</sub> heterocycloalkyl C<sub>0-10</sub> alkyl(carbonyl)<sub>0-1</sub>, heterocycloalkyl, C<sub>1-4</sub>acylamino C<sub>0-10</sub> alkyl, C<sub>0-10</sub> alkylamino C<sub>0-10</sub> alkyl, C<sub>0-10</sub> alkylamino C<sub>0-10</sub> alkylaminocarbonyl, di-(C<sub>1-10</sub> alkyl)amino C<sub>0-10</sub> alkyl, arylC<sub>0-10</sub> alkylamino C<sub>0-10</sub> alkyl, (arylC<sub>0-10</sub> alkyl)<sub>2</sub>amino C<sub>0-10</sub> alkyl, C<sub>3-8</sub> cycloalkyl C<sub>0-10</sub> alkylamino C<sub>0-10</sub> alkyl, C<sub>3-8</sub> heterocyclyl C<sub>0-10</sub> alkylamino C<sub>0-10</sub> alkyl, (C<sub>3-8</sub> cycloalkyl C<sub>0-10</sub> alkyl)<sub>2</sub>amino C<sub>0-10</sub> alkyl, (C<sub>3-8</sub> heterocyclyl C<sub>0-10</sub> alkyl)<sub>2</sub>amino C<sub>0-10</sub> alkyl, C<sub>3-8</sub> cycloalkyl C<sub>0-10</sub> alkyl aminocarbonylamino, (C<sub>1-10</sub> alkyl)<sub>2</sub>aminocarbonylamino, (aryl C<sub>1-10</sub> alkyl)<sub>1-2</sub>aminocarbonylamino, C<sub>0-10</sub> alkyl aminocarbonylamino, C<sub>3-8</sub> heterocyclyl C<sub>0-10</sub> alkyl aminocarbonylamino, (C<sub>1-10</sub> alkyl)<sub>2</sub>aminocarbonyl C<sub>0-10</sub> alkyl, (aryl C<sub>1-10</sub> alkyl)<sub>1-2</sub>aminocarbonyl C<sub>0-10</sub> alkyl, C<sub>0-10</sub> alkyl aminocarbonyl C<sub>0-10</sub> alkyl, C<sub>3-8</sub> cycloalkyl C<sub>0-10</sub> alkyl aminocarbonyl C<sub>0-10</sub> alkyl, C<sub>3-8</sub> heterocyclyl C<sub>0-10</sub> alkyl aminocarbonyl C<sub>0-10</sub> alkyl,

aryl C<sub>0-10</sub> alkyl aminocarbonyl C<sub>0-10</sub> alkyl, (C<sub>1-10</sub> alkyl)<sub>2</sub>aminocarbonyl,  
 (aryl C<sub>1-10</sub> alkyl)<sub>1-2</sub>aminocarbonyl, C<sub>1-10</sub> alkoxy (carbonyl)<sub>0-1</sub> C<sub>0-10</sub> alkyl,  
 C<sub>0-10</sub> alkyl carbonylamino(C<sub>0-10</sub> alkyl), C<sub>0-10</sub> alkoxy carbonylamino(C<sub>0-10</sub> alkyl),  
 carboxy C<sub>0-10</sub> alkylamino, carboxy C<sub>0-10</sub> alkyl, carboxy C<sub>3-8</sub> cycloalkyl, C<sub>1-10</sub> alkoxy,  
 C<sub>1-10</sub>alkyloxy C<sub>0-10</sub>alkyl, C<sub>1-10</sub> alkylcarbonyloxy, C<sub>0-10</sub>alkyl carbonylC<sub>0-10</sub>alkoxy,  
 C<sub>3-8</sub> heterocyclyl C<sub>0-10</sub> alkylcarbonyloxy, C<sub>3-8</sub> cycloalkyl C<sub>0-10</sub> alkylcarbonyloxy,  
 aryl C<sub>0-10</sub> alkylcarbonyloxy, C<sub>1-10</sub> alkylcarbonyloxy amino,  
 C<sub>3-8</sub> heterocyclyl C<sub>0-10</sub> alkylcarbonyloxy amino,  
 C<sub>3-8</sub> cycloalkyl C<sub>0-10</sub> alkylcarbonyloxy amino, aryl C<sub>0-10</sub> alkylcarbonyloxy amino,  
 (C<sub>1-10</sub> alkyl)<sub>2</sub>aminocarbonyloxy, (aryl C<sub>0-10</sub> alkyl)<sub>1-2</sub>aminocarbonyloxy,  
 (C<sub>3-8</sub> heterocyclyl C<sub>0-10</sub> alkyl)<sub>1-2</sub>aminocarbonyloxy,  
 (C<sub>3-8</sub> cycloalkyl C<sub>0-10</sub>alkyl)<sub>1-2</sub>aminocarbonyloxy, hydroxy (carbonyl)<sub>0-1</sub> C<sub>0-10</sub>alkyl,  
 hydroxycarbonylC<sub>0-10</sub>alkoxy, hydroxycarbonylC<sub>0-10</sub>alkyloxy, C<sub>1-10</sub> alkylthio,  
 C<sub>1-10</sub> alkylsulfinyl, aryl C<sub>0-10</sub> alkylsulfinyl, C<sub>3-8</sub> heterocyclyl C<sub>0-10</sub> alkylsulfinyl,  
 C<sub>3-8</sub> cycloalkyl C<sub>0-10</sub> alkylsulfinyl, C<sub>1-10</sub> alkylsulfonyl, aryl C<sub>0-10</sub> alkylsulfonyl,  
 C<sub>3-8</sub> heterocyclyl C<sub>0-10</sub> alkylsulfonyl, C<sub>3-8</sub> cycloalkyl C<sub>0-10</sub> alkylsulfonyl,  
 C<sub>1-10</sub> alkylsulfonylamino, aryl C<sub>1-10</sub> alkylsulfonylamino,  
 C<sub>3-8</sub> heterocyclyl C<sub>1-10</sub> alkylsulfonylamino, C<sub>3-8</sub> cycloalkyl C<sub>1-10</sub> alkylsulfonylamino,  
 cyano, nitro, perfluoroC<sub>1-6</sub>alkyl, and perfluoroC<sub>1-6</sub>alkoxy;

wherein R<sup>5</sup> is optionally substituted with one or more groups chosen from: OH, (C<sub>1-6</sub>)alkoxy,  
 halogen, CO<sub>2</sub>H, CN, O(C=O)C<sub>1-6</sub> alkyl, NO<sub>2</sub>, trifluoromethoxy, trifluoroethoxy,  
 -O<sub>b</sub>(C<sub>1-10</sub>)perfluoroalkyl, and NH<sub>2</sub>; and

R<sup>6</sup> is halogen, hydroxy, C<sub>1-4</sub> alkoxy, CONH<sub>2</sub>, and C<sub>1-4</sub> alkylamino, wherein R<sup>6</sup> is optionally  
 substituted with one or more groups chosen from: OH, (C<sub>1-6</sub>)alkoxy, halogen,  
 CO<sub>2</sub>H, CN, O(C=O)C<sub>1-6</sub> alkyl, NO<sub>2</sub>, trifluoromethoxy, trifluoroethoxy, -O<sub>b</sub>(C<sub>1-10</sub>)  
 perfluoroalkyl, NH<sub>2</sub>, and -O<sub>b</sub>(C<sub>1-10</sub>)alkyl optionally substituted with one or more  
 halogen moieties.

## 2. – 4.(Cancelled)

5. (Original) The compound of Claim 2, wherein in  $R^3$ , said heteroaryl is chosen from azabenzimidazole, acridinyl, carbazoyl, cinnolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzodihydrofuranyl, 1,3-benzodioxolyl, 2,3-dihydro-1,4-benzodioxinyl, indolyl, quinolyl, quinoxalinyl, isoquinolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidyl, pyrazinyl, piridazinyl, tetrahydroquinolinyl, thiadiazolyl, oxadiazolyl, triazolyl, imidizopyridinyl, tetrazolyl, and indanyl; wherein said  $R^3$  is optionally substituted with one or more substituents independently chosen from  $R^5$ .

6. (Original) The compound of Claim 5, wherein said heteroaryl is chosen from azabenzimidazole, benzimidazolyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzodihydrofuranyl, 1,3-benzodioxolyl, 2,3-dihydro-1,4-benzodioxinyl, indolyl, quinolyl, quinoxalinyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidyl, pyrazinyl, piridazinyl, tetrahydroquinolinyl, thiadiazolyl, triazolyl, imidizopyridinyl, and tetrazolyl; wherein said  $R^3$  is optionally substituted with one or more substituents independently chosen from  $R^5$ .

7. (Currently amended) The compound of Claim 1, wherein  $R^1$  is ~~chosen from hydrogen, and~~  $C_{1-3}$  alkyl optionally substituted with one to seven fluorine atoms.

8. (Original) The compound of Claim 7, wherein  $R^1$  is ~~chosen from hydrogen and methyl~~.

9. (Original) The compound of Claim 1, wherein  $R^4$  is chosen halogen,  $C_{1-6}$  alkyl, and  $(CH_2)_n$ -phenyl, wherein  $R^4$  is optionally substituted with one or more substituents each independently chosen from cyano, carboxy, halogen, hydroxy, oxo,  $C_{1-4}$  alkoxy, and  $C_{1-4}$  alkylthio.

10. (Original) The compound of Claim 9, wherein  $R^4$  is chosen from halogen and  $C_{1-6}$  alkyl, optionally substituted with one or more substituents each independently chosen from cyano, carboxy, halogen, hydroxy, oxo,  $C_{1-4}$  alkoxy, and  $C_{1-4}$  alkylthio.

11. (Original) The compound of Claim 10, wherein  $R^4$  is  $CH_3$ .

12. – 13. (Cancelled)

14. (Original) The compound of Claim 1, wherein R<sup>5</sup> is chosen from: hydrogen, halogen, (carbonyl)<sub>0-1</sub>C<sub>1-10</sub> alkyl, C<sub>3-8</sub> cycloalkyl C<sub>0-10</sub> alkyl(carbonyl)<sub>0-1</sub>, C<sub>3-8</sub> heterocycloalkyl C<sub>0-10</sub> alkyl(carbonyl)<sub>0-1</sub>, C<sub>0-10</sub> alkylamino C<sub>0-10</sub> alkyl, C<sub>0-10</sub> alkylamino C<sub>0-10</sub> alkylaminocarbonyl, arylC<sub>0-10</sub> alkylamino C<sub>0-10</sub> alkyl, C<sub>3-8</sub> cycloalkyl C<sub>0-10</sub> alkylamino C<sub>0-10</sub> alkyl, C<sub>3-8</sub> heterocyclyl C<sub>0-10</sub> alkylamino C<sub>0-10</sub> alkyl, C<sub>3-8</sub> cycloalkyl C<sub>0-10</sub> alkyl aminocarbonylamino, C<sub>0-10</sub> alkyl aminocarbonylamino, C<sub>3-8</sub> heterocyclyl C<sub>0-10</sub> alkyl aminocarbonylamino, C<sub>0-10</sub> alkyl aminocarbonyl C<sub>0-10</sub> alkyl, C<sub>3-8</sub> cycloalkyl C<sub>0-10</sub> alkyl aminocarbonyl C<sub>0-10</sub> alkyl, C<sub>3-8</sub> heterocyclyl C<sub>0-10</sub> alkyl aminocarbonyl C<sub>0-10</sub> alkyl, aryl C<sub>0-10</sub> alkyl aminocarbonyl C<sub>0-10</sub> alkyl, (C<sub>1-10</sub> alkyl)<sub>2</sub>aminocarbonyl, C<sub>1-10</sub> alkoxy (carbonyl)<sub>0-1</sub>C<sub>0-10</sub> alkyl, C<sub>0-10</sub> alkyl carbonylamino(C<sub>0-10</sub> alkyl), C<sub>0-10</sub> alkoxy carbonylamino(C<sub>0-10</sub> alkyl), carboxy C<sub>0-10</sub> alkylamino, carboxy C<sub>0-10</sub> alkyl, carboxy C<sub>3-8</sub> cycloalkyl, C<sub>1-10</sub> alkoxy, hydroxy (carbonyl)<sub>0-1</sub>C<sub>0-10</sub>alkyl, C<sub>0-10</sub>alkyl carbonylC<sub>0-10</sub>alkoxy, hydroxycarbonylC<sub>0-10</sub>alkoxy, hydroxycarbonylC<sub>0-10</sub>alkyloxy, cyano, nitro, perfluoroC<sub>1-6</sub>alkyl, and perfluoroC<sub>1-6</sub>alkoxy; wherein R<sup>5</sup> is optionally substituted with one or more groups chosen from: OH, (C<sub>1-6</sub>)alkoxy, halogen, CO<sub>2</sub>H, CN, O(C=O)C<sub>1-C6</sub> alkyl, NO<sub>2</sub>, trifluoromethoxy, trifluoroethoxy, -O<sub>b</sub>(C<sub>1-10</sub>)perfluoroalkyl, and NH<sub>2</sub>.

15. (Original) The compound of Claim 14, wherein R<sup>2</sup> is chosen from hydrogen and C<sub>1-4</sub> alkyl, optionally substituted with one or more substituents independently selected from halogen, hydroxy, C<sub>1-4</sub> alkoxy, and C<sub>1-4</sub> alkylamino.

16. (Currently amended) ~~The compound of Claim 1,~~ A compound selected from:  
*N*-[3-(trifluoromethyl)pyridin-2-yl] -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(5-cyanopyridin-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[6-(trifluoromethyl)pyridin-2-yl] -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[3-cyano-pyridin-2-yl] -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(3-methyl-benzimidazol-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(5-nitro-benzimidazol-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(1,3-benzothiazol-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;

*N*-(4-chloro-1,3-benzothiazol-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(6-methyl-1,3-benzothiazol-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(6-methoxy-1,3-benzothiazol-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(5,6-dimethyl-1,3-benzothiazol-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(4-methyl-1,3-benzothiazol-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(5-fluoropyridin-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(5-cyclopropyl-1,3,4-thiadiazol-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(2-methyl-3-bromo-pyrid-4-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N,N*-methyl(pyridin-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(5-methylpyridin-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[5-(trifluoromethyl)pyridin-2-yl] -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(5-chloropyridin-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(1,3-pyrimid-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(1,3-pyrazin-4-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(benzimidazol-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(2-methyl-pyrid-4-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(pyridin-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(pyridin-3-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(pyridin-4-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[(3-carboxamido)-pyridin-6-yl] -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(6-cyanopyridin-3-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(6-methylpyridin-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(6-aminopyridin-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[(6-trifluoromethyl)-pyrid-3-yl] -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(6-ethylpyridin-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(6-fluoro-1,3-benzothiazol-2-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(2-ethylpyridin-4-yl) -4-methyl-6-methyl-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(2-ethylpyridin-4-yl) -4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(2-methyl-pyrid-4-yl) -4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(pyridin-2-yl) -4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(pyridin-3-yl) -4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(pyridin-4-yl) -4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;

*N*-(6-cyanopyridin-3-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(6-methylpyridin-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(6-aminopyridin-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[(6-trifluoromethyl)pyrid-3-yl]-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(2-chloro-pyrid-4-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(5-fluoro-pyrid-3-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(6-ethylpyridin-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(2-methyl-3-bromo-pyrid-4-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*, *N*-methyl(pyridin-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(5-methylpyridin-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[5-(trifluoromethyl)pyridin-2-yl]-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(5-chloropyridin-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(1,3-pyrimid-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(1,3-pyrazin-4-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(5-fluoropyridin-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(benzimidazol-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[(5-carboxyl)pyrid-2-yl]-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[(4-carboxyl)phenyl]-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[(4-carboxyl-3-chloro)phenyl]-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[2-chloro(4-methoxycarbonyl)phenyl]-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(1,3-pyrimid-4-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[5-(ethoxycarbonyl)-1,3-thiazol-2-yl]-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[4-(trifluoromethyl)-5-(ethoxycarbonyl)-1,3-thiazol-2-yl]-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[4-hydroxy-5-(ethoxycarbonyl)-1,3-pyrimid-2-yl]-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(6-methylpyridin-2-yl)-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[(4-carboxamido)phenyl]-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(2-methyl-pyrid-4-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(pyridin-3-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(4,6-dimethylpyridin-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(benzimidazol-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;

*N*-(6-methylpyridin-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(6-cyanopyridin-3-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(5-fluoropyridin-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-(5-chloropyridin-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[(5-(trifluoromethyl)pyridin-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[(5-carboxyl)-pyridin-2-yl]-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;  
*N*-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-6,6-ethylene-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -acetamide;  
*N*-[4,6-dimethyl-pyridin-2-yl]-6,6-ethylene-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -acetamide;  
*N*-(benzimidazol-2-yl)-6,6-ethylene-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -acetamide;  
*N*-[5-cyano-pyridin-2-yl]-6,6-ethylene-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -acetamide;  
*N*-(1,3-pyrimid-4-yl)-6,6-ethylene-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -acetamide;  
*N*-[3-methyl-pyridin-2-yl]-6,6-ethylene-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -acetamide;  
*N*-[(5-carboxamido)pyridin-2-yl]-6,6-ethylene-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -acetamide;  
*N*-(isoquinolin-3-yl)-6,6-ethylene-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -acetamide;  
*N*-[6-(trifluoromethyl)pyridin-2-yl]-6,6-ethylene-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -acetamide;  
*N*-(4-azabenzimidazol-2-yl)-6,6-ethylene-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -acetamide;  
*N*-(1*H*-imidazo[4,5-*b*]pyridin-2-yl)-4-methyl-6-chloro-3-oxo-4-aza-5 $\alpha$ -androst-5-en-17 $\beta$ -acetamide;

and/or a

pharmaceutically acceptable salt salts and stereoisomers thereof.

17. – 18.(Cancelled)

19. (Previously amended) A pharmaceutical composition comprising a compound of any one of Claims 1 or a salt or stereoisomer thereof and a pharmaceutically acceptable carrier.

20. (Currently amended) A composition of Claim 19, further comprising an active ingredient selected from: an estrogen or an estrogen derivative, alone or in combination with a progestin or progestin derivative, a bisphosphonate, an antiestrogen or a selective estrogen receptor modulator, an  $\alpha$ v $\beta$ 3 integrin receptor antagonist, a cathepsin K inhibitor, ~~an~~ a HMG-CoA reductase inhibitor, an osteoclast vacuolar ATPase inhibitor, an antagonist of VEGF binding to osteoclast receptors, an activator of peroxisome proliferator-activated receptor  $\gamma$ , calcitonin, a calcium receptor antagonist, parathyroid hormone or analog thereof, a growth hormone secretagogue, human growth hormone, insulin-like growth factor, a p38 protein kinase inhibitor, bone morphogenetic protein, an inhibitor of BMP antagonism, a prostaglandin derivative, vitamin D or vitamin D derivative, vitamin



K or vitamin K derivative, ipriflavone, fluoride salts, dietary calcium supplements, and osteoprotegerin.

21. (Currently amended) A composition of Claim 20 ~~Claim 21~~, wherein said bisphosphonate is alendronate.

22. to 31. (Cancelled)